Get Savvy Investor
Stock Alerts

Latest news on ‘Health & Drug’

  • Diabetes pill controversy shows rift in FDA ranks

    WASHINGTON (AP) – The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week [...]

  • Merck To Close 16 Facilities, Part Of Schering Deal

    Merck & Co. (MRK) said Thursday that it would close eight research sites and eight manufacturing plants to hit cost-saving targets promised as a result of last year’s takeover of [...]

  • Health overhaul first provisions start to kick in

    WASHINGTON (AP) — The first stage of President Barack Obama’s health care overhaul is expected to provide coverage to about 1 million uninsured Americans by next year, according to government [...]

  • Covidien to Pay $2.6 Billion for Device Maker Ev3

    (Bloomberg) — Covidien Plc, the medical-equipment company spun off from Tyco International Ltd., agreed to buy ev3 Inc. for $2.6 billion to add products for heart disease.
    Covidien will pay [...]

  • Pfizer cuts hundreds of jobs in Britain and Ireland

    Andrew Clark in New York – largest drugs company, Pfizer, is to dispose of eight factories and cut 6,000 jobs, including hundreds of positions in Britain and Ireland, as it [...]

  • Investors dump shares of Wellpoint, down 2.2% (WLP)

    WellPoint (NYSE:WLP) is one of today’s worst performing stocks, down 2.2% to $50.19. The S&P is currently trading 1% lower to 1,116 and the Dow Jones Industrial Average is trading [...]

  • P&G 3Q profit dips despite sales jump

    CINCINNATI (AP) — Consumer products giant Procter & Gamble Co. reported Thursday that its profit fell 1 percent in its third quarter, hurt by charges including from the U.S. health [...]

  • For $520 Million, AstraZeneca Settles Case Over Marketing of a Drug

    By DUFF WILSON – AstraZeneca has completed a deal to pay $520 million to settle federal investigations into marketing practices for its blockbuster schizophrenia drug, Seroquel, the Attorney General, Eric [...]

  • Charles River, Chinese Pharma Firm Ink $1.6B Deal

    HONG KONG – Charles River Laboratories plans to buy Shanghai-based pharmaceutical outsourcing provider WuXi PharmaTech in a $1.6 billion cash-and-stock deal, the companies announced Monday.
    Once complete, the deal could mark [...]

  • Judge Invalidates Human Gene Patent

    NY Times – A federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents [...]

Disclaimer:
This site includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. savvyinvestor.com and its information providers do not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice, or advocate the purchase or sale of any security or investment or any particular investment trading strategy.